Jyong Biotech Ltd.

Jyong Biotech Ltd. (MENS) priced its initial public offering on Jun 18, 2025 at $7.50 per share, and listed on Nasdaq Global Market. At the IPO price its market capitalization was about $570.2M. Joseph Stone was lead-left underwriter. Sichenzia Ross Ference Carmel and Conyers Dill & Pearman advised the company and VCL Law advised the underwriters.

Jyong Biotech Ltd. is a Taiwan-based biotechnology company, founded in 2002, developing and commercializing plant-derived new drugs mainly for urinary system diseases, with an initial focus on the U.S., EU and Asian markets. It covers drug discovery, clinical trials and regulatory work.

Status

IPO

Ticker

MENS

Exchange

Nasdaq Global Market

Priced

Jun 18, 2025

IPO price

$7.50

Market cap at IPO price

$570.2M

First filed

Aug 17, 2023

Underwriters

Joseph Stone

Company counsel

Sichenzia Ross Ference Carmel and Conyers Dill & Pearman

Underwriters' counsel

VCL Law

Sector

Biotech & pharma

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.